

Supplementary Table S4. Clinical and molecular profile of RA patients naïve to b/tsDMARDs who initiated JAKi (Cohort 3).

Clinical parameters	RA naïve patients starting JAKi (n=36)	3-months (n=34)	6-months (n=33)	12-months (n=27)
Male/Female (n/n)	9/27	-	-	-
Age, years (mean ± SD)	54.94 ± 10.36	-	-	-
Disease evolution, years (mean ± SD)	10.90 ± 10.01	-	-	-
TJC (mean ± SD)	8.36 ± 6.76	1.35 ± 1.94****	1.52 ± 4.58****	1.33 ± 3.11****
SJC (mean ± SD)	4.44 ± 4.35	0.35 ± 0.77****	0.33 ± 1.43****	0.56 ± 2.17****
DAS28-CRP (mean ± SD)	4.59 ± 1.13	2.42 ± 0.87****	2.13 ± 0.99****	2.31 ± 1.18****
SDAI (mean ± SD)	26.80 ± 12.80	9.78 ± 5.93****	7.61 ± 9.25****	8.60 ± 9.36****
CDAI (mean ± SD)	25.82 ± 12.38	9.24 ± 5.38****	7.20 ± 9.28****	7.93 ± 8.68****
HAQ (mean ± SD)	1.26 ± 0.46	2.06 ± 3.75*	2.56 ± 4.93	0.78 ± 0.36*
Smoking (n, %)	11, 30.56%	-	-	-
Hypertension (n, %)	8, 22.22%	-	-	-
Laboratory parameters				

CRP, mg/mL (mean ± SD)	9.80 ± 11.66	5.49 ± 14.53	4.10 ± 6.41**	6.71 ± 12.86
ESR, mm/h (mean ± SD)	23.02 ± 27.67	16.12 ± 13.55	20.81 ± 20.50	25.48 ± 37.17
ACPAs positivity (n, %)	25, 69.44%	1, 2.78%	25, 69.44%	17, 47.22%
RF positivity (n, %)	27, 75.00%	26, 72.22%	26, 72.22%	20, 55.56%
Treatments				
Corticosteroids (n, %)	27, 75.00%	-	-	-
NSAIDs (n, %)	29, 80.55%	-	-	-
cDMARDs (n, %)	28, 77.78%	-	-	-

TJC (Tender Joint Count); SJC (Swollen Joint Count); DAS28-CRP (Disease Activity Score); SDAI (Simplified Disease Activity Index); CDAI (Clinical Disease Activity Index); HAQ (Health Assessment Questionnaire); CRP (C-reactive protein); ESR (Erythrocyte sedimentation rate); ACPA (Anti-citrullinated protein antibodies); RF (Rheumatoid Factor); NSAID (Non-steroidal anti-inflammatory drug); cDMARD (Conventional DMARDs). Statistical significance levels respect to baseline time were designated as follows: (****) <0.0001 p-value; (***) <0.001 p-value; (**) <0.01 p-value; (*) <0.05 p-value.